Pyc Therapeutics Ltd has released a press release.
RP11 Clinical Trial Update - Amended
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- RP11 Clinical Trial Update
- Extension of RP11 Single Dose Study Into Multiple Dose Study
- Initial Dosing Completed in Cohort 1 of RP11 MAD Study
- Commencement of RP11 Multiple Dose Trial
- RP11 Drug Candidate Safe and Well Tolerated
Later from PYC Therapeutics
- Visual Improvement in Multiple RP11 Patients
- PYC to Start Human Trials in Second Blinding Eye Disease
- Appendix 4E and Audited Financial Statements
- FDA Grants Rare Pediatric Disease Designation to PYC-001
- Notice of Annual General Meeting/Proxy Form
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics